Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
Ricardo Azêdo de Luca MontesMolla HuqTimothy GodfreyShereen OonAlicia CalderoneRangi Kandane-RathnayakeWorawit LouthrenooShue-Fen LuoYeong-Jian Jan WuVera GolderAisha LateefSandra V NavarraLeonid ZamoraLaniyati HamijoyoSargunan SockalingamYuan AnZhanguo LiYasuhiro KatsumataMasayoshi HarigaiMadelynn ChanFiona GoldblattSean O'NeillChak Sing LauJiacai ChoAlberta HoiChetan S KaryekarEric F MorandMandana NikpourPublished in: Advances in rheumatology (London, England) (2024)
This study suggests a steroid-sparing benefit for most commonly used standard of care immunosuppressants used in SLE treatment, some of which were associated with an increased likelihood of attaining LLDAS, or reduced incidence of flares. It also highlights the unmet need for effective treatments in lupus.